首页> 美国卫生研究院文献>ClinicoEconomics and Outcomes Research: CEOR >Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain Corrigendum

【2h】

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain Corrigendum

机译：Gemtuzumab ozogamicin在西班牙CD-33阳性急性髓性白血病患者初线治疗的成本效果分析勘误

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277.

机译：Mareque M，Montesinos P，Font P等人。 Clinicoecon没有任何东西。 2021; 13：263-277。

著录项

期刊名称 ClinicoEconomics and Outcomes Research: CEOR
作者

展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 1
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [J] . Maria Mareque, Pau Montesinos, Patricia Font, ClinicoEconomics and Outcomes Research . 2021,第a期

机译：Gemtuzumab ozogamicin在西班牙CD-33阳性急性髓性白血病患者术语中的成本效果分析
2. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials [J] . HillsR.K., CastaigneS., AppelbaumF.R., The lancet oncology . 2014,第9期

机译：成年急性髓细胞性白血病患者在诱导化疗中加用吉妥单抗奥佐米星：一项来自随机对照试验的个体患者数据的荟萃分析
3. Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia. [J] . McHayleh W, Foon K, Redner R, Cancer: A Journal of the American Cancer Society . 2010,第12期

机译：Gemtuzumab ozogamicin作为70岁或以上的急性髓性白血病患者的一线治疗。
4. Design of optimal disease and patient-specific chemotherapy protocols for the treatment of Acute Myeloid Leukaemia (AML) [C] . E. Pefani, N. Panoskaltsis, A. Mantalaris International Symposium on Process Systems Engineering . 2012

机译：用于治疗急性髓性白血病（AML）的最佳疾病和患者特异性化疗方案的设计
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [O] . Maria Mareque, Pau Montesinos, Patricia Font, 2021

机译：Gemtuzumab ozogamicin在西班牙CD-33阳性急性髓性白血病患者术语中的ozogamicin成本效果分析
7. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [O] . Maria Mareque, Pau Montesinos, Patricia Font, 2021

机译：Gemtuzumab ozogamicin在西班牙CD-33阳性急性髓性白血病患者术语中的ozogamicin成本效果分析

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain Corrigendum

摘要

著录项

相似文献

相关主题

期刊订阅